318 related articles for article (PubMed ID: 28721019)
1. Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives.
Ran X; Yang K
Drug Des Devel Ther; 2017; 11():2007-2014. PubMed ID: 28721019
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
[TBL] [Abstract][Full Text] [Related]
3. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
4. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C
Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181
[TBL] [Abstract][Full Text] [Related]
5. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
6. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant PD-1/PD-L1 axis blockade for patients with head and neck squamous cell carcinoma.
Huang S; Xiong C; Tan K
Am J Otolaryngol; 2023; 44(6):103985. PubMed ID: 37442083
[TBL] [Abstract][Full Text] [Related]
8. [Current events in immunotherapy for upper aerodigestive tract cancer].
Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumour cell PD-L1 test for head and neck cancers.
Kulasinghe A; Kenny L; Punyadeera C
Oral Oncol; 2017 Dec; 75():6-7. PubMed ID: 29224824
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma.
Tran L; Allen CT; Xiao R; Moore E; Davis R; Park SJ; Spielbauer K; Van Waes C; Schmitt NC
Cancer Immunol Res; 2017 Dec; 5(12):1141-1151. PubMed ID: 29097421
[TBL] [Abstract][Full Text] [Related]
11. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
12. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.
Li Y; Li F; Jiang F; Lv X; Zhang R; Lu A; Zhang G
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27438833
[TBL] [Abstract][Full Text] [Related]
13. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers of response to PD-1/PD-L1 inhibition.
Maleki Vareki S; Garrigós C; Duran I
Crit Rev Oncol Hematol; 2017 Aug; 116():116-124. PubMed ID: 28693793
[TBL] [Abstract][Full Text] [Related]
15. The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis.
Wang BC; Cao RB; Li PD; Fu C
Cancer Med; 2019 Oct; 8(13):5969-5978. PubMed ID: 31436392
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
17. PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report.
Nagasaka M; Zaki M; Kim H; Raza SN; Yoo G; Lin HS; Sukari A
J Immunother Cancer; 2016; 4():83. PubMed ID: 27895920
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.
Cristina V; Herrera-Gómez RG; Szturz P; Espeli V; Siano M
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671550
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint immunotherapy in head and neck cancers.
Zolkind P; Uppaluri R
Cancer Metastasis Rev; 2017 Sep; 36(3):475-489. PubMed ID: 28836124
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers.
Economopoulou P; Kotsantis I; Psyrri A
Curr Treat Options Oncol; 2016 Aug; 17(8):40. PubMed ID: 27315066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]